North China Pharmaceutical Company.Ltd (SHA:600812)

SHA:600812 Revenue

North China Pharmaceutical Company.Ltd had revenue of 1.79B CNY in the quarter ending September 30, 2026, a decrease of -19.00%. This brings the company's total for the last twelve months to 7.77B, down -20.70% year-over-year. In the year 2025, North China Pharmaceutical Company.Ltd had annual revenue of 9.24B, down -6.36%. That makes North China Pharmaceutical Company.Ltd the 6,955th largest company in the world by revenue and 988th in China.

• Revenue (ttm): 7.77B
• Revenue Growth: -20.70%
• P/S Ratio: 1.04
• Revenue / Employee: 778.82K
• Employees: 9,972
• Market Cap: 8.03B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Chemical Drug Substance 4.10B 44.8%
• Chemical API 2.29B 25.1%
• Biological Agents 1.61B 17.7%
• Pharmaceuticals and Other Logistics Trade 633.25M 6.9%
• Pharmaceutical Intermediates 384.08M 4.2%
• Other 120.61M 1.3%

By Geography

Chart

• China 7.18B 78.6%
• Foreign 1.95B 21.4%

Fiscal year ended Dec 31, 2025 See the full SHA:600812 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	9.24B	-627.92M	-6.36%
Dec 31, 2024	9.87B	-250.63M	-2.48%
Dec 31, 2023	10.12B	-379.75M	-3.62%
Dec 31, 2022	10.50B	115.37M	1.11%
Dec 31, 2021	10.38B	-1.11B	-9.64%

Data Source: S&P Global Market Intelligence Last updated: Oct 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 28, 2026

Data Sources Report a data error